Sexually Transmitted Diseases

In Gilead’s BICSTaR trial of their full HIV treatment regimen Biktarvy, 97% of treatment-naïve adults and 96% of treatment-experienced adults achieved virological suppression after 1 year.

The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.

Merck recently announced results looking at their islatravir implant studied for HIV prevention for 3 months. The long-term goal is to have the implant last 12 months following administration.

Children living with HIV have a new once-daily treatment option to maintain virologic suppression.

Comparing 2020 to 2019, investigators saw a reduction in the number of HIV tests, the number of in-person consultations, and new enrollments in care, due to the disruption in HIV care throughout the COVID-19 pandemic.

There are MSM who are indicated for PrEP use that don’t use it, and vice versa, the study authors found.

This promising class of therapy is an expanding treatment option for people who are looking for HIV prevention offerings.

The TakeMeHome program, a public-private partnership to distribute HIV self-test home kits to at-risk populations, is reaching at-risk individuals who weren’t otherwise accessing testing.

The HIV In-hospital Mortality Prediction (HIV-IMP) risk score showed good discrimination and calibration and may be useful in guiding clinical decision-making.

A recent study measured premature deaths among people with HIV by sex, race, and HIV risk factor.

Pregnant women infected with certain strains of human papillomavirus during pregnancy had a nearly fourfold greater risk of preterm labor.

People who inject drugs are at high-risk for HIV infection, but very few are interested in PrEP prescriptions.

Mortality rates of children with HIV may be underreported due to lack of patient follow-up and the usage of routine program data.

Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.

England has been meeting and exceeding its HIV diagnosis and treatment goals set by UNAIDS.

Parentless youth living on the streets had the highest rates of HIV and death, but extended-family living situations were not necessarily better than institutional care.

The therapy, known as EBT-101, works by eliminating HIV-infected DNA from the genome.

To address PrEP implementation in Kenya, a team of researchers evaluated practices and contextual modifications across public HIV clinics.

Antiretroviral therapy for HIV offers a protective outcome against preterm birth for pregnant women with HIV.

The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.

Higher HIV viral loads and additional heart disease factors increase the risk as well.

Changes in perceptions about the severity of HIV with advances in treatment and efforts to normalize living with the disease may create challenges for HIV prevention, a new study from the Netherlands suggests.

Islatravir exerts multiple mechanisms against HIV, demonstrates treatment effectiveness with doravirine, and is a potential weekly or monthly oral PrEP.

Optimizing delivery of HIV preexposure prophylaxis will take more than access to health care, according to a recent analysis of PrEP use behaviors among adults in an integrated health system.

Despite heightened cardiovascular disease (CVD) risk, too few get drugs at appropriate dose, researchers say.

It is important to go out into the local communities to educate people about PrEP as countries try to scale up with the World Health Organization’s (WHO) PrEP recommendations.

Human papillomavirus (HPV) impacts millions of Americans, and new study sought to address the epidemiology of HPV and high-grade squamous intraepithelial lesions (HSIL).

Global use of HIV pre-exposure prophylaxis has risen as more countries have adopted World Health Organization recommendations.

New Imbokodo findings show a 4-dose regimen was only about 25% effective in preventing HIV in at-risk women, hindering progress for the vaccine.